Is Gilead Sciences Inc.'s Moat Filling Up With Sand?
Gilead Sciences might be on the verge of losing a large chunk of its hepatitis C drug revenues. Here's why.
Why Isis Pharmaceuticals, Inc. Exploded Higher By 19% in May
Isis Pharmaceuticals' stock was off to the races again in May. Find out what two factors led shares notably higher last month, and whether this momentum can continue.